Marina Elena Cazzaniga

Author

Also Known As

Alexandre Belot, Andrea Biondi, Cecilia Bussolari, Daniela Galimberti, Eric Hoste, Giuseppe Citerio, Giuseppe Foti, M CAZZANIGA, M Cazzaniga, M E Cazzaniga

319

Publications

14K

Citations

H-Index

Concepts

All Affiliations

Azienda Ospedaliera San Gerardo Istituti di Ricovero e Cura a Carattere Scientifico University of Milano-Bicocca Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Mario Negri Institute for Pharmacological Research

About

Marina Elena Cazzaniga is an author at Azienda Ospedaliera San Gerardo specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	48	3.4K
2	Health Sciences	8	8	473
3	Social Sciences	2	2	132
4	Nursing	1	1	61
5	Biomedical Engineering	1	1	11

Marina Elena Cazzaniga

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, The Lancet Oncology Phase 3Gastrointestinal OncologyMedicinePathologyColorectal Cancer	2015	1.1K
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Journal of Clinical Oncology	2022	626
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings Guido Cavaletti, David R. Cornblath, Ingemar S. J. Merkies, Annals of Oncology Health SciencesPeripheral Nerve InjuryPain MedicineReliability FindingsDiabetic Neuropathy	2012	284
Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer William C. Dooley, Britt‐Marie Ljung, U. Veronesi, JNCI Journal of the National Cancer Institute	2001	275
A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers Andrea DeCensi, C. Robertson, Giuseppe Viale, JNCI Journal of the National Cancer Institute	2003	221
Clinical pattern and associations of oxaliplatin acute neurotoxicity Andreas A. Argyriou, Guido Cavaletti, Chiara Briani, Cancer	2012	218
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study Shubham Pant, Martin Schüler, Gopa Iyer, The Lancet Oncology Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor	2023	175
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin Paola Alberti, Emanuela Rossi, David R. Cornblath, Annals of Oncology NeurotoxicologyPharmacologyNeuropathic PainPatient-reported Outcome MeasuresSame Coin	2013	171
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone Paolo Lissoni, Sandro Barni, Sofia Meregalli, British Journal of Cancer Cancer Endocrine TherapyBreast OncologyMedicinePharmacologyNeuroendocrine Disorder	1995	149
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients Roser Velasco, Jordi Bruna, Chiara Briani, Journal of Neurology Neurosurgery & Psychiatry	2013	145

Page 1